Pfizer Inc

Pfizer’s Braftovi phase‑three success shows a 30 % PFS boost for metastatic colorectal cancer, but high monthly costs and reimbursement hurdles mean strategic pricing and supply‑chain upgrades will be critical to unlocking its $120 m+ market potenti…

Pfizer’s new license with Novavax’s Matrix‑M adjuvant and sale of its ViiV stake signal a sharpened focus on high‑margin vaccine and biotech opportunities, boosting R&D speed and future profitability.

Pfizer’s breakthrough BRAF‑targeted colorectal cancer results and new obesity drug plans highlight its dual strategy to dominate oncology while opening a high‑margin consumer market, boosting investor confidence.

Pfizer’s BREAKWATER trial shows BRAFTOVI® boosts response rates in BRAF‑V600E metastatic colorectal cancer, offering a new targeted option and strengthening Pfizer’s oncology growth beyond COVID‑era revenue.

Pfizer’s new AI partnership with Boltz, PBC and its mRNA patent case show how cutting‑edge tech and legal battles shape drug‑discovery speed, costs and future investor outlook.

Pfizer’s 2026 reset focuses on cost discipline and emerging markets—psychedelics and drug‑delivery tech—offering a unique, long‑term growth play for investors.

Pfizer’s strategic focus on oncology and chronic disease, value‑based pricing, patent protection and targeted M&A positions it for sustained growth despite market uncertainty.

Pfizer’s post‑COVID pivot: how oncology, obesity and potential M&A moves reshape its market‑access, patent and risk profile.

Pfizer’s 2026 guidance signals flat revenue but tighter costs, while $900 million licensing deals with Adaptive Biotechnologies boost its autoimmune pipeline—balancing steady earnings with targeted growth.

Pfizer cuts Swiss staff, sees cost savings, boosts margins; phase‑III study shows Tukysa extends survival for HER2‑positive breast cancer, while a new GLP‑1 partnership targets fast‑track obesity treatment.